Login Register

16 August 2017

New Vaccination Claim Provides Flexibility and Convenience

UK, Milton Keynes, August 16, 2017 – The convenience to revaccinate at up to 12 month intervals for IBR is now available with Bovilis® IBR Marker Live from MSD Animal Health (a division of Merck & Co., Inc., Kenilworth, NJ, USA).

As the only live IBR vaccine offering 12 months duration of immunity, it provides flexibility and convenience to tailor vaccination schedules to the farm system.

Andrew Montgomery, MSD Animal Health veterinary adviser, explains that with infectious bovine rhinotracheitis (IBR) it can be difficult to know the status of the herd, with the potential for uninfected, newly infected and latently infected animals to all be present.

“The disease cycle of IBR means latently infected animals are carriers of IBR and are the pilot light for infection, shedding the virus during times of stress, while newly infected animals produce large quantities of virus over a short time.”

Mr Montgomery says that the new product claim which allows revaccination at intervals of up to 12 months, offers a real advantage from an on-farm disease management perspective.

“The SPC (summary of product characteristics) for Bovilis® IBR Marker Live states that following the primary vaccination course of a single dose of the vaccine from 3 months of age followed by the first re-vaccination 6 months later, booster revaccinations can be given up to 12 months later, providing a convenient solution for whole herd vaccination.

“Not only this, after the primary vaccination with Bovilis® IBR Marker Live, there is the option to revaccinate 6 months later and then up to 12 months later with Bovilis® IBR Marker Live or Bovilis® IBR Marker Inac, offering flexibility to tailor the vaccination programme to the herd situation.”

He adds that Bovilis® IBR Marker Live can be mixed and administered with Bovilis® BVD or given on the same day as Bovilis® Bovipast RSP, adding another layer of convenience.

“The new product claim puts a fresh perspective on how IBR can be controlled at a practical farm level, and is a very positive step forward for the UK cattle industry.”

For further information, please refer to the product data sheets at www.noahcompendium.co.uk and SPCs and/ or speak to your local MSD Animal Health area manager.


Use medicines responsibly. Please visit www.noah.co.uk/responsible for more information. Bovilis® IBR Marker Live and Marker Inac contain BHV-1 strain GK/D (gE¯). Bovilis® BVD is an inactivated vaccine containing cytopathogenic BVD virus strain C86. Bovilis® Bovipast RSP contains inactivated BRSV, PI3 and Mannheimia haemolytica A1. Legal caterogies POM-V. Bovilis® IBR Marker Live, Bovilis® IBR Marker Inac, Bovilis® BVD and Bovilis® Bovipast RSP are the property of Intervet International B.V. or affiliated companies or licensors and is protected by copyrights, trademark and other intellectual property laws. For information regarding side effects, precautions, warnings and contra-indications please refer to the datasheet at www.noahcompendium.co.uk